Pineapple has been used as part of traditional folk medicine since ancient times and it continues to be present in various herbal preparations. Bromelain is a complex mixture of protease extracted from the fruit or stem of the pineapple plant. Although the complete molecular mechanism of action of bromelain has not been completely identified, bromelain gained universal acceptability as a phytotherapeutic agent due to its history of safe use and lack of side effects. Bromelain is widely administered for its well-recognized properties, such as its anti-inflammatory, antithrombotic and fibrinolytic affects, anticancer activity and immunomodulatory effects, in addition to being a wound healing and circulatory improvement agent. The current review describes the promising clinical applications and therapeutic properties of bromelain.
During the sixteenth and seventeenth centuries, the pineapple plants were introduced to Asia Pacific and became the first commercial crop (1). Bromelain is a complex natural mixture of proteolytic enzymes derived from pineapple (Ananas cosmosus) and possesses notable therapeutic properties. There is continued interest in bromelain, which has been used for many years in folk medicine for various health problems. The potential therapeutic value of bromelain is due to its biochemical and pharmacological properties, and the main ingredient in crude bromelain is a proteolytic enzyme termed glycoprotein, which is in addition to insoluble materials, such as minerals, colored pigments, protease inhibitors, organic acids and organic solvents (2,3). As yet, eight proteolytically active components have been isolated from bromelain (4). Proteinases are considered to be the most active fraction, which comprise ~2% of the total proteins (5). Bromelain exerts its activity over a pH range of 4.5 to 9.5 (6). It is possible to isolate and purify bromelain using various methods. For commercial use, bromelain is prepared by centrifugation, ultrafilteration and lyophilization (7). The composition of bromelain varies based on the method of purification and the source; stem bromelain contains high quantities of protease content when compared with bromelain derived from the fruit (8). It was demonstrated that the majority of the physiological activity of bromelain may not be due to single proteolytic fraction, and it is likely that the beneficial effects of bromelain are due to multiple factors (9). Bromelain has not only been used to treat various health problems, it is also popular as a nutritional supplement to promote health. Bromelain is absorbed into the human intestines and remains biologically active with a half-life of ~6–9 h (10). The highest concentration of bromelain was identified in the blood one hour after administration (11). Bromelain increases bioavailability and reduces the side effects that are associated with various antibiotics (12,13). Furthermore, bromelain acts as an immunomodulator, is anti-metastatic, anti-edematous, anti-thrombotic and anti-inflammatory (14,15). These findings indicate that bromelain may present as a promising candidate for the development of future anticancer therapeutic strategies. Notably, although numerous studies have been conducted regarding bromelain there are limited reviews that document the complete anticancer activity of bromelain. The focus of the current review was evidence for the anticancer effects of bromelain, which involve direct suppression of cancer cells, as well as evaluating the anti-inflammatory activity and immune system function modulation of bromelain. The future direction of research and the prospects for bromelain-based cancer therapy are presented.
Anti-inflammatory activity of bromelain
Inflammation is pivotal in the development of cancer during cellular transformation, proliferation, angiogenesis, invasion and metastasis. It has been demonstrated that suppression of chronic inflammation may reduce the cancer incidence and also inhibit cancer progression (16). Cyclooxigenase-2 (COX-2) is an important component of cancer-associated inflammation that is involved in the synthesis of prostaglandin E2 (PGE-2). PGE-2 is a pro-inflammatory lipid that also acts as an immunosuppressant, as well as a promoter of tumor progression (17). COX-2 converts arachidonic acid into PGE-2 and promotes tumor angiogenesis and cancer progression (18). It has been shown that bromelain downregulates COX-2 and PGE-2 expression levels in murine microglial cells and human monocytic leukemia cell lines (19). Bromelain activates the inflammatory mediators, including interleukin (IL)-1β, IL-6, interferon (INF)-γ and tumor necrosis factor (TNF)-α in mouse macrophage and human peripheral blood mononuclear cells (PBMC) (20–22). These results indicated that bromelain potentially activates the healthy immune system in association with the rapid response to cellular stress. Conversely, bromelain reduces IL-1β, IL-6 and TNF-α secretion when immune cells are already stimulated in the condition of inflammation-induced over production of cytokines (23,24). Studies have shown that bromelain reduced the expression of INF-γ and TNF-α in inflammatory bowel disease (25). A study demonstrated that bromelain diminished the cell damaging effect of advanced glycation end products by proteolytic degradation of receptor of advanced glycation end products (25) and controlled the inflammation (25). The cell surface marker, cluster of differentiation (CD)44 is expressed by cancer and immune cells directly involved in cancer growth and metastasis. Furthermore, CD44 regulates lymphocyte requirement at the site of inflammation (26,27). Bromelain was shown to reduce the level of CD44 expression on the surface of mouse and human tumor cells, and regulate lymphocyte homing and migration to the sites of inflammation (28). Furthermore, bromelain modulates the expression of transforming growth factor (TGF)-β, one of the major regulators of inflammation in patients affected by osteomyelofibrosis and rheumatoid arthritis (29,30). There are various studies that report the immunomodulatory effect of bromelain (31–34). Bromelain activates natural killer cells and augments the production of granulocyte-macrophage-colony stimulating factor, IL-2, IL-6 and decreases the activation of T-helper cells (35,36). Thus, bromelain decreases the majority of inflammatory mediators and has demonstrated a significant role as an anti-inflammatory agent in various conditions (37).
Anticancer activity of bromelainEffect on cell growth and survival pathways
In normal cells, cellular growth and proliferation are highly regulated, and imbalances of the cell cycle may lead to abandoned cellular growth and result in transformation to cancer cells. There are various pathways that are contained within cells to protect their DNA from damage resulting from toxicity and genomic instability (38). Checkpoint proteins are critical for monitoring the normal activity of the cell cycle. Tumor cells frequently lose checkpoint controls; therefore, regulation of cell cycle progression is employed one of the important approaches for cancer chemotherapy (39). It has been demonstrated that bromelain inhibits nuclear factor-κB (NF-κB) translocation through G2/M arrest to apoptosis in human epidermoid carcinoma and melanoma cells (40). The process of apoptosis is fundamental in the developmental and homeostatic maintenance of complex biological systems. Failure of normal apoptotic mechanisms contributes to transformation of cells and provides a growth advantage to cancer cells (41). The apoptotic mechanism is characterized by cell shrinkage, chromatin condensation, DNA fragmentation and the activation of specific cysteine proteases, known as caspases (42). Generally, apoptosis is achieved by either mitochondrial pathways (intrinsic) or death receptor pathways (extrinsic). The mitochondrial pathway involves p53 functioning as a transcription factor to upregulate the expression of Bcl-2-like protein 4 (Bax), a pro-apoptotic protein. Bax antagonizes B-cell lymphoma 2 (Bcl-2), an anti-apoptotic protein that is present in the mitochondrial membrane (43). The protective effect of Bcl-2 on the mitochondrial membrane is disrupted when the Bax/Bcl-2 ratio is increased. This facilitates the release of cytochrome c into the cytosol and binds with apoptotic protease activating factor-1 to form an apoptosome complex. It initiates the caspase cascade via activation of caspase-9 and results in cell death via enzymatic destruction of cytoplasmic proteins and DNA (44). Bromelain has been shown to selectively induce apoptosis in tumor cells by upregulation of p53 expression and initiation of the mitochondrial apoptotic pathway via increased Bax expression and cytochrome c release (45). In addition, bromelain decreases the activity of cell survival regulators, such as Akt and extracellular signal-regulated kinases, thus promoting apoptotic cell death in tumors (46). In vitro bromelain treatment of established mouse tumor cell lines resulted in inhibition of cell growth and matrigel invasion capacities (47–50). It has been demonstrated that bromelain treatment significantly reduced the growth of gastric carcinoma Kato-III cell lines (51).
Effect on angiogenesis and metastasis
The metastatic spread of tumor cells from the original site is the cause of the high mortality rates associated with cancer. There are at least four interrelated biological events required for tumor metastasis: Angiogenesis, cell adhesion, cell invasion and cell proliferation (52). The interesting aspect of the anticancer activity of bromelain is its inhibitory effect on cancer metastasis. Bromelain potentially interferes with tumor metastasis progression at a variety of pivotal points (53). Bromelain inhibits cell surface adhesion proteins that are essential in cell adhesion, migration and inflammation (54). This inhibition is predominantly due to suppression of NF-κB activation. Furthermore, bromelain inhibits the invasiveness of human cancer cells by suppressing matrix metalloproteinase (MMP)-9 expression (55,56) through inhibiting activator protein 1 (AP-1) and NF-κB signaling pathways (42,57). A previous study demonstrated that bromelain initially suppresses the phosphorylation of NF-κB activation and then decreases the phosphorylation of c-Jun N-terminal kinases and subsequently AP-1 activation (58). In malignancies, there is a mutual association between platelets and tumor cells. Tumor cells initiate platelet activation, as well as the platelet-based production of multiple factors facilitating angiogenesis. Additionally, tumor cells, to varying degrees, possess the capacity to surround themselves with platelets, forming tumor-platelet aggregates that protect tumor cells from immune recognition (59). Oral administration of bromelain, as assessed by in vitro assays resulted in a reduction of platelet aggregation and activation (60). A previous study demonstrated that in vitro bromelain treatment of platelets from healthy volunteers significantly reduced platelet count (61). The ability of bromelain to inhibit platelet activation is associated with its proteolytic activity (17). Thus, the anti-platelet activity of bromelain interferes with platelet-mediated cancer growth and progression, and prevents the generation of tumor-platelet aggregates by un-coating cancer cells and exposing them to the immune system (62).
The stimulation of new blood vessel growth is an essential step for tumor growth and metastasis in order to provide for the metabolic needs of rapidly proliferating malignant cells. Angiogenesis is regulated by a variety of pro-angiogenic genes and signaling molecules, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), platelet-derived growth factors, hypoxia-inducible factors, angiopoetin-1 and 2, and MMPs (63). Bromelain has demonstrated an anti-angiogenic effect in various cancer cell lines (47,64). Bromelain has been shown to regulate a variety of pro-angiogenic growth factors, enzymes and transcription factors including bFGF, VEGF, angiopoetin-1 and 2, COX-2, MMP-9, AP-1 and NF-κB (41,65). Furthermore, bromelain has been shown to inhibit the angiogenic response to FGF-2 stimulation in mouse endothelial cells and decrease the expression of MMP-9, an enzyme involved in tissue remodeling that is important for the growth of new blood vessels (66). In addition, bromelain treatment decreased the levels of the angiogenic biomarkers, COX-2 and VEGF in hepatocellular carcinoma cells, and resulted in a reduction in tumor neo-capillary density when compared with untreated cells (67). In addition to its inhibitory effects on angiogenesis, bromelain has been demonstrated to affect a number of cellular adhesion molecules involved in the processes of tumor growth and metastasis (47).
Antimicrobial activity
Bromelain supplementation protects animals against diarrhea caused by bacterial enterotoxins from Escherichia coli and Vibrio cholerae (68). Bromelain acts as anti-adhesion agent by modifying the receptor attachment sites and influences the intestinal secretory signaling pathways (69,70). In addition to its ability to counter certain effects of particular intestinal pathogens and its synergism with antibiotics, these two mechanisms are indicative of the benefits of bromelain against specific infections. In vitro evidence also suggests that bromelain exerts antihelminthic activity against the gastrointestinal nematodes, Trichuris muris and Heligmosomoides polygyrus (71,72). Conversely, bromelain acts as an anti-fungal agent by stimulating phagocytosis and respiratory burst killing of Candida albicans when incubated with trypsin in vitro (73). Pityriasis lichenoides chronica is an infectious skin disease and bromelain reportedly caused complete resolution of this condition (74). Bromelain has been documented to increase blood and urine levels of certain antibiotics in humans (75–77). Combined bromelain and antibiotic therapy was shown to be more effective than antibiotics alone in pneumonia, bronchitis, cutaneous Staphylococcus infection, thrombophlebitis, cellulitis, pyelonephritis, and in perirectal and rectal abscesses (78), sinusitis (79) and urinary tract infections (80). A combination of bromelain, trypsin, and rutin has been administered as an adjuvant therapy in combination with antibiotics for children with sepsis (77). A combination of bromelain with enzymes derived from Aspergillus niger improved protein utilization in elderly nursing home patients (81). Another study demonstrated that bromelain, in combination with sodium alginate, sodium bicarbonate and essential oils, significantly improved dyspeptic symptoms (82). In addition, bromelain has been administered successfully as a digestive enzyme to treat intestinal disorders, pancreatectomy and exocrine pancreas insufficiency (83). Finally, the combination of ox bile, pancreatin, and bromelain is effective in lowering stool fat excretion in patients with pancreatic steatorrhea, resulting in symptomatic improvements in pain, flatulence and stool frequency (84).
Clinical applications
Currently bromelain is administered for numerous clinical applications due to its therapeutic effects in the treatment of inflammation and soft tissue injuries. A clinical study demonstrated that bromelain administered to boxers completely cleared all bruises on the face and haematomas of the orbits, lips, ears, chest and arms in four days (85). It has been demonstrated that orally administered bromelain is absorbed by the gut without losing its biological properties and significantly reduces the edema in traumatically-induced hind leg edema in rats (86). In vitro and in vivo analysis determined that administration of bromelain prevents aggregation of human blood platelets. Furthermore, in vitro and in vivo analysis indicated that bromelain administration prevents aggregation of human blood platelets and minimizes the severity of angina pectoris and transient ischemic attacks (35). Studies have also demonstrated the fibrinolytic activity (87), inhibition of thrombus formation (88) and platelet aggregation reduction resulting from bromelain treatment (89,90). In addition, bromelain administration controlled the angina attacks and resulted in the disappearance of symptoms in hypertensive patients. Furthermore, angina attacks reappeared following discontinuation of bromelain after variable periods of time (up to 2 months) (87). Another study described that bromelain was effectively involved in the treatment of acute thrombophlebitis by decreasing the walking impairment in patients, and symptoms of inflammation, including skin temperature, tenderness, edema and pain (90). It has been shown that bromelain facilitated functional recovery of the heart by limiting myocardial injury in ischemia experiments (90). Bromelain also increased aortic flow, and reduced the infarct size and the degree of apoptosis (90,91). A previous study demonstrated that bromelain treatment reduced apoptosis and endothelial cell damage in hepatic ischemia (92). In addition, there is an evidence that bromelain protected against ischemic injury in skeletal muscle (93). In vivo and in vitro studies have shown that bromelain dissolved arteriosclerotic plaque in rabbit aorta and it clearly explains the potent fibrinolytic activity of bromelain, which functions by breaking down cholesterol plaques (94,95). In experimental animals, bromelain exerts an anti-hypertensive effect when administered for prolonged time periods. Furthermore, it increases vessel wall permeability to oxygen and nutrients while increasing blood fluidity (96). In patients suffering from inflammatory bowl diseases, bromelain administration reduces a variety of pro-inflammatory molecules, such as INF-γ and colony stimulating factor (23). It has been reported that bromelain was successfully used in the treatment of ulcerative colitis and patients showed rapid improvement of symptoms (97). Furthermore, bromelain administration resulted in significant decrease in pain and stiffness in patients with knee osteoarthritis (98). In a murine model of acute asthma, bromelain decreased airway reactivity and sensitivity to irritants, decreased markers of lung inflammation (including infiltration by eosinophils and leukocytes) and moderated aspects of local airway immunity (99,100). Numerous reports have documented the benefits of bromelain for sinusitis (101,102). A previous study showed that administration of bromelain among children suffering from acute sinusitis shortened the duration of symptoms and accelerated recovery when compared with usual care regimens (103). Furthermore, sinusitis patients that received bromelain demonstrated complete resolution of breathing difficulties and inflammation of the nasal mucosa (104) and, in a rat model of rheumatoid arthritis, treatment with bromelain combined with cyclosporine reduced destructive arthritis and inflammation (105,106). In addition, a clinical study demonstrated that bromelain was administered to patients with arthritic joint swelling and a significant to complete decrease in soft tissue swelling was observed (107).
Conclusion
Bromelain has been recognized as a safe and successful type of therapeutic agent, and is being used by individuals worldwide for a number of ailments, such as bronchitis, sinusitis, arthritis and inflammation. Various findings from traditional and clinical reports indicate that bromelain may be an effective anticancer therapeutic agent. From the in vitro and in vivo data that is currently available, bromelain demonstrates immunomodulatory and anti-neoplastic effects, in addition to anti-inflammatory and anti-microbial effects. The above-mentioned experimental evidence clearly demonstrates that bromelain exhibits efficacious chemopreventive capabilities entailing antitumor-initiating and -promoting effects via inhibition of tumor development, which is underlined by induction of p53, shifts in the Bax/Bcl-2 ratio, induction of caspases, decreases in Cox-2 expression and inhibition of the NF-κB pathway by regulating MAPK and Akt/PKB signaling pathways. Future studies in this area may lead to promising results for bromelain-based cancer therapy, anti-microbial agents and health supplements.
ReferencesMortonJPineappleFruits of Warm ClimatesJulia F. MortonMiami, FL18281987ScopesRKProtein Purification: Principles and Practice2ndSpringer-VerlagNew York, NY41651982ArnonRShapiraEAntibodies to papain. A selective fractionation according to inhibitory capacityBiochemistry639423950196710.1021/bi00864a0414169495OtaSMooreSSteinWHPreparation and chemical properties of purified stem and fruit bromelainsBiochemistry3180185196410.1021/bi00890a00714163938MurachiTYasuiMYasudaYPurification and physical characterization of stem bromelainBiochemistry34855196410.1021/bi00889a00914114503HaleLPGreerPKTrinhCTJamesCLProteinase activity and stability of natural bromelain preparationsInt Immunopharmacol5783793200510.1016/j.intimp.2004.12.00715710346DevakateRVPatilVVWajeSSThoratBNPurification and drying of bromelainSepar Purif Tech64259264200910.1016/j.seppur.2008.09.012CastellJVFriedrichGKuhnCSPoppeGEIntestinal absorption of undegraded proteins in men: presence of bromelain in plasma after oral intakeAm J Physiol273G139G14619979252520MaurerHRBromelain: Biochemistry, pharmacology and medical useCell Mol Life Sci5812341245200110.1007/PL0000093611577981Mialovyts'kaOAEffect of phlogenzym in long-term treatment of patients with multiple sclerosisLik Sprava1091132003(In Ukrainian)WhiteRRCrawleyFEVelliniMRovatiLABioavailability of 125I bromelain after oral administration to ratsBiopharm Drug Dispos9397403198810.1002/bod.25100904083207859TaussigSJBatkinSBromelain, the enzyme complex of pineapple (Ananas comosus) and its clinical application. An updateJ Ethnopharmacol22191203198810.1016/0378-8741(88)90127-43287010BrienSLewithGWalkerAHicksSMMiddletonDBromelain as a treatment for osteoarthritis: a review of clinical studiesEvid Based Complement Alternat Med1251257200410.1093/ecam/neh03515841258HaleLPProteolytic activity and immunogenicity of oral bromelain within the gastrointestinal tract of miceInt Immunopharmacol4255264200410.1016/j.intimp.2003.12.01014996417SarkarFHLiYCell signaling pathways altered by natural chemopreventive agentsMutat Res5555364200410.1016/j.mrfmmm.2004.04.01515476851HuangJRWuCCHouRCJengKCBromelain inhibits lipopolysaccharide-induced cytokine production in human THP-1 monocytes via the removal of CD14Immunol Invest37263277200810.1080/0882013080208362218569070BhuiKPrasadSGeorgeJShuklaYBromelain inhibits COX-2 expression by blocking the activation of MAPK regulated NF-kappa B against skin tumor-initiation triggering mitochondrial death pathwayCancer Lett282167176200910.1016/j.canlet.2009.03.00319339108GaspaniLLimiroliEFerrarioPBianchiMIn vivo and in vitro effects of bromelain on PGE(2) and SP concentrations in the inflammatory exudate in ratsPharmacology658386200210.1159/00005619111937778DesserLRehbergerAPaukovitsWProteolytic enzymes and amylase induce cytokine production in human peripheral blood mononuclear cells in vitroCancer Biother9253263199410.1089/cbr.1994.9.2537529614EngwerdaCRAndrewDMurphyMMynottTLBromelain activates murine macrophages and natural killer cells in vitroCell Immunol210510200110.1006/cimm.2001.179311485347EngwerdaCRAndrewDLadhamsAMynottTLBromelain modulates T cell and B cell immune responses in vitro and in vivoCell Immunol2106675200110.1006/cimm.2001.180711485354BarthHGuseoAKleinRIn vitro study on the immunological effect of bromelain and trypsin on mononuclear cells from humansEur J Med Res10325331200516131473OnkenJEGreerPKCalingaertBHaleLPBromelain treatment decreases secretion of pro-inflammatory cytokines and chemokines by colon biopsies in vitroClin Immunol126345352200810.1016/j.clim.2007.11.00218160345HaleLPGreerPKTrinhCTGottfriedMRTreatment with oral bromelain decreases colonic inflammation in the IL-10-deficient murine model of inflammatory bowel diseaseClin Immunol116135142200510.1016/j.clim.2005.04.01115936249StopperHSchinzelRSebekovaKHeidlandAGenotoxicity of advanced glycation end products in mammalian cellsCancer Lett190151156200310.1016/S0304-3835(02)00626-212565169MakrydimasGZagorianakouNZagorianakouPAgnantisNJCD44 family and gynaecological cancerIn Vivo17633640200314758731SubramaniamVGardnerHJothySSoluble CD44 secretion contributes to the acquisition of aggressive tumor phenotype in human colon cancer cellsExp Mol Pathol83341346200710.1016/j.yexmp.2007.08.00717945213MassaguéJTGFbeta in CancerCell134215230200810.1016/j.cell.2008.07.00118662538BierieBMosesHLTumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancerNat Rev Cancer6506520200610.1038/nrc192616794634LeipnerJItenFSallerRTherapy with proteolytic enzymes in rheumatic disordersBioDrugs15779789200110.2165/00063030-200115120-0000111784210VelliniMDesideriDMilaneseAOminiCDaffonchioLHernandezABrunelliGPossible involvement of eicosanoids in the pharmacological action of bromelainArzneimittelforschung3611011219863006709InoueKMotonagaADainakaJNishimuraTHashiiHYamateKUedaFKimuraKEffect of etodolac on prostaglandin E2 biosynthesis, active oxygen generation and bradykinin formationProstaglandins Leukot Essent Fatty Acids51457462199410.1016/0952-3278(94)90065-57708812Oh-ishiSUchidaYUenoAKatoriMBromelian, a thiolprotease from pineapple stem, depletes high molecular weight kininogen by activation of Hageman factor (Factor XIII)Thromb Res14665672197910.1016/0049-3848(79)90121-X483261SeligmanBBromelain: An anti-inflammatory agentAngiology13508510196210.1177/00033197620130110313992714GiaccaSClinical experiences on the action of bromelin in peripheral venous diseases and in chronic bronchitic statesMinerva Med561041965(In Italian)MossJNFrazierCVMartinGJBromelains. The pharmacology of the enzymesArch Int Pharmacodyn Ther145166189196314077679De-GiuliMPirottaFBromelain, interaction with some protease inhibitor and rabbit specific antiserumDrugs Exp Clin Res421231978ChobotovaKVernallisABMajidFABromelain's activity and potential as an anti-cancer agent: current evidence and perspectivesCancer Lett290148156201010.1016/j.canlet.2009.08.00119700238BeuthJBraunJMModulation of murine tumor growth and colonization by bromelaine, an extract of the pineapple plant (Ananas comosum L.)In Vivo19483485200515796214BáezRLopesMTSalasCEHernándezMIn vivo antitumoral activity of stem pineapple (Ananas comosus) bromelainPlanta Med7313771383200710.1055/s-2007-99022117893836ZavadovaEDesserLMohrTStimulation of reactive oxygen species production and cytotoxicity in human neutrophils in vitro and after oral administration of a polyenzyme preparationCancer Biother10147152199510.1089/cbr.1995.10.1477663574EckertKGrabowskaEStangeRSchneiderUEschmannKMaurerHREffects of oral bromelain administration on the impaired immunocytotoxicity of mononuclear cells from mammary tumor patientsOncol Rep611911199199910523679SnowdenHMRenfrewMJWoolridgeMWTreatments for breast engorgement during lactationCochrane Database Syst Rev2CD000046200111405948Guimarães-FerreiraCARodriguesEGMortaraRACabralHSerranoFARibeiro-dos-SantosRTravassosLRAntitumor effects in vitro and in vivo and mechanisms of protection against melanoma B16F10-Nex2 cells by fastuosain, a cysteine proteinase from Bromelia fastuosaNeoplasia9723733200710.1593/neo.0742717898868TysnesBBMaurerHRPorwolTProbstBBjerkvigRHooverFBromelain reversibly inhibits invasive properties of glioma cellsNeoplasia3469479200110.1038/sj.neo.790019611774029MantovaniAAllavenaPSicaABalkwillFCancer-related inflammationNature454436444200810.1038/nature0720518650914JuhaszBThirunavukkarasuMPantRZhanLPenumathsaSVSecorERJrSrivastavaSRaychaudhuriUMenonVPOtaniHBromelain induces cardioprotection against ischemia-reperfusion injury through Akt/FOXO pathway in rat myocardiumAm J Physiol Heart Circ Physiol294H1365H1370200810.1152/ajpheart.01005.200718192224FerrisRLGrandisJRNF-kappaB gene signatures and p53 mutations in head and neck squamous cell carcinomaClin Cancer Res1356635664200710.1158/1078-0432.CCR-07-154417908953ChenFBeezholdKCastranovaVTumor promoting or tumor suppressing of NF-kappa B, a matter of cell context dependencyInt Rev Immunol27183204200810.1080/0883018080213032718574736HouRCChenYSHuangJRJengKCCross-linked bromelain inhibits lipopolysaccharide-induced cytokine production involving cellular signaling suppression in ratsJ Agric Food Chem5421932198200610.1021/jf052390k16536595TaussigSJSzekerczesJBatkinSInhibition of tumour growth in vitro by bromelain, an extract of the pineapple plant (Ananas comosus)Planta Med51538539198510.1055/s-2007-96959617345291KleefRDeloheryTMBovbjergDHSelective modulation of cell adhesion molecules on lymphocytes by bromelain protease 5Pathobiology64339346199610.1159/0001640709159029GerardGAnti-cancer therapy with bromelainAgress32612741972NieperHAA program for the treatment of cancerKrebs61241271974PhilchenkovACaspases: potential targets for regulating cell deathJ Cell Mol Med8432444200410.1111/j.1582-4934.2004.tb00468.x15601572LiQWithoffSVermaIMInflammation-associated cancer: NF-kappaB is the lynchpinTrends Immunol26318325200510.1016/j.it.2005.04.00315922948OltersdorfTElmoreSWShoemakerARArmstrongRCAugeriDJBelliBABrunckoMDeckwerthTLDingesJHajdukPJAn inhibitor of Bcl-2 family proteins induces regression of solid tumoursNature435677681200510.1038/nature0357915902208NettiCBandiGLPecileAAnti-inflammatory action of proteolytic enzymes of animal vegetable or bacterial origin administered orally compared with that of known anti-phlogistic compoundsFarmaco Prat84534661972SmythRDBrennanRMartinGJSystemic biochemical changes following the oral administration of a proteolytic enzyme, bromelainArch Int Pharmacodyn Ther136230236196213914543GarbinFHarrachTEckertKMaurerHRBromelain proteinase-f9 augments human lymphocyte-mediated growth-inhibition of various tumor cells in vitroInt J Oncol5197203199421559575GläserDHilbergTThe influence of bromelain on platelet count and platelet activity in vitroPlatelets173741200610.1080/0953710050019748916308185KalraNBhuiKRoyPSrivastavaSGeorgeJPrasadSShuklaYRegulation of p53, nuclear factor kappaB and cyclooxygenase-2 expression by bromelain through targeting mitogen-activated protein kinase pathway in mouse skinToxicol Appl Pharmacol2263037200810.1016/j.taap.2007.08.01217889918KimJKKimYNaKMSurhYJKimTY[6]-Gingerol prevents UVB-induced ROS production and COX-2 expression in vitro and in vivoFree Radic Res41603614200710.1080/1071576070120989617454143KarlsenMHovdenAOVogelsangPTysnesBBAppelSBromelain treatment leads to maturation of monocyte-derived dendritic cells but cannot replace PGE2 in a cocktail of IL-1β, IL-6, TNF-α and PGE2Scand J Immunol74135143201110.1111/j.1365-3083.2011.02562.x21449940WuSYHuWZhangBLiuSWangJMWangAMBromelain ameliorates the wound microenvironment and improves the healing of firearm woundsJ Surg Res176503509201210.1016/j.jss.2011.11.102722341346WallaceJMNutritional and botanical modulation of the inflammatory cascade - eicosanoids, cyclooxygenases, and lipoxygenases - as an adjunct in cancer therapyIntegr Cancer Ther1737200210.1177/15347354020010010214664746ManosroiAChankhampanCManosroiWManosroiJToxicity reduction and MMP-2 stimulation of papain and bromelain loaded in elastic niosomesJ Biomed Nanotechnol8720729201210.1166/jbn.2012.145822888742MynottTLGuandaliniSRaimondiFFasanoABromelain prevents secretion caused by Vibrio cholerae and Escherichia coli enterotoxins in rabbit ileum in vitroGastroenterology113175184199710.1016/S0016-5085(97)70093-39207276ChandlerDSMynottTLBromelain protects piglets from diarrhoea caused by oral challenge with K88 positive enterotoxigenic Escherichia coliGut43196202199810.1136/gut.43.2.19610189844MynottTLLukeRKChandlerDSOral administration of protease inhibits enterotoxigenic Escherichia coli receptor activity in piglet small intestineGut382832199610.1136/gut.38.1.288566855StepekGLoweAEButtleDJDuceIRBehnkeJMIn vitro and in vivo anthelmintic efficacy of plant cysteine proteinases against the rodent gastrointestinal nematode, Trichuris murisParasitology132681689200610.1017/S003118200500973X16448585StepekGButtleDJDuceIRLoweABehnkeJMAssessment of the anthelmintic effect of natural plant cysteine proteinases against the gastrointestinal nematode, Heligmosomoides polygyrus, in vitroParasitology130203211200510.1017/S003118200400622515727070BrakebuschMWintergerstUPetropoulouTNotheisGHusfeldLBelohradskyBHAdamDBromelain is an accelerator of phagocytosis, respiratory burst and Killing of Candida albicans by human granulocytes and monocytesEur J Med Res6193200200111410400MassimilianoRPietroRPaoloSSaraPMicheleFRole of bromelain in the treatment of patients with pityriasis lichenoides chronicaJ Dermatolog Treat18219222200710.1080/0954663070129914717671882TinozziSVenegoniAEffect of bromelain on serum and tissue levels of amoxicillinDrugs Exp Clin Res439441978LuertiMVignaliMLInfluence of bromelain on penetration of antibiotics in uterus, salpinx and ovaryDrugs Exp Clin Res445481978ShahidSKTurakhiaNHKundraMShanbagPDaftaryGVSchiessWEfficacy and safety of phlogenzym - a protease formulation, in sepsis in childrenJ Assoc Physicians India50527531200212164403NeubauerRAA plant protease for potentiation of and possible replacement of antibioticsExp Med Surg19143160196114479142RyanREA double-blind clinical evaluation of bromelains in the treatment of acute sinusitisHeadache71317196710.1111/j.1526-4610.1967.hed0701013.x4859824MoriSOjimaYHiroseTSasakiTHashimotoYThe clinical effect of proteolytic enzyme containing bromelain and trypsin on urinary tract infection evaluated by double blind methodActa Obstet Gynaecol Jpn1914715319724587187GladeMJKendraDKaminskiMVJrImprovement in protein utilization in nursing-home patients on tube feeding supplemented with an enzyme product derived from Aspergillus niger and bromelainNutrition17348350200110.1016/S0899-9007(01)00528-711369177Knill-JonesRPPearceHBattenJWilliamsRComparative trial of Nutrizym in chronic pancreatic insufficiencyBMJ42124197010.1136/bmj.4.5726.214919118BalakrishnanVHareendranANairCSDouble-blind cross-over trial of an enzyme preparation in pancreatic steatorrhoeaJ Assoc Physicians India2920720919816912244PellicanoRStronaSSimondiDReggianiSPallavicinoFSguazziniCBonaguraAGRizzettoMAstegianoMBenefit of dietary integrators for treating functional dyspepsia: a prospective pilot studyMinerva Gastroenterol Dietol55227235200919829282BlonsteinJLControl of swelling in boxing injuriesPractitioner18578196013801601UhligGSeifertJThe effect of proteolytic enzymes (traumanase) on posttraumatic edemaFortschr Med995545561981(In German)7239381NieperHAEffect of bromelain on coronary heart disease and angina pectorisActa Med Empirica52742781978NieperHADecrease of the incidence of coronary heart infarct by Mg- and K-orotate and bromelainActa Med Empirica126146181977SeligmanBOral bromelains as adjuncts in the treatment of acute thrombophlebitisAngiology202226196910.1177/0003319769020001034885019GutfreundAETaussigSJMorrisAKEffect of oral bromelain on blood pressure and heart rate of hypertensive patientsHawaii Med J371431461978659096GailhoferGWilders-TruschnigMSmolleJLudvanMAsthma caused by bromelain: an occupational allergyClin Allergy18445450198810.1111/j.1365-2222.1988.tb02894.x3233722BahdeRPalmesDMininEStratmannUDillerRHaierJSpiegelHUBromelain ameliorates hepatic microcirculation after warm ischemiaJ Surg Res1398896200710.1016/j.jss.2006.10.00417292418BloomerRJThe role of nutritional supplements in the prevention and treatment of resistance exercise-induced skeletal muscle injurySports Med37519532200710.2165/00007256-200737060-0000517503877FeltonGEFibrinolytic and antithrombotic action of bromelain may eliminate thrombosis in heart patientsMed Hypotheses611231133198010.1016/0306-9877(80)90134-66256612Lotz-WinterHOn the pharmacology of bromelain: an update with special regard to animal studies on dose-dependent effectsPlanta Med56249253199010.1055/s-2006-9609492203073ShibayamaYAn experimental study into the cause of acute haemorrhagic gastritis in cirrhosisJ Pathol149307313198610.1002/path.17114904073093656KaneSGoldbergMJUse of bromelain for mild ulcerative colitisAnn Intern Med132680200010.7326/0003-4819-132-8-200004180-0002610766699WalkerAFBundyRHicksSMMiddletonRWBromelain reduces mild acute knee pain and improves well-being in a dose-dependent fashion in an open study of otherwise healthy adultsPhytomedicine9681686200210.1078/09447110232162126912587686SecorERCarsonWFSinghAPensaMGuernseyLASchrammCMThrallRSOral bromelain attenuates inflammation in an ovalbumin-induced murine model of asthmaEvid Based Complement Alternat Med56169200810.1093/ecam/nel11018317550SecorERJrCarsonWFIVCloutierMMGuernseyLASchrammCMWuCAThrallRSBromelain exerts anti-inflammatory effects in an ovalbumin-induced murine model of allergic airway diseaseCell Immunol2376875200510.1016/j.cellimm.2005.10.00216337164SeltzerAPAdjunctive use of bromelains in sinusitis: a controlled studyEye Ear Nose Throat Mon461281128819674864820BraunJMSchneiderBBeuthHJTherapeutic use, efficiency and safety of the proteolytic pineapple enzyme Bromelain-POS in children with acute sinusitis in GermanyIn Vivo19417421200515796206ZatuchniGIColombiDJBromelains therapy for the prevention of episiotomy painObstet Gynecol2927527819675334992AhleNWHamletMPEnzymatic frostbite eschar debridement by bromelainAnn Emerg Med1610631065198710.1016/S0196-0644(87)80759-X3307553RovenskáESvíkKStancíkováMRovenskýJEnzyme and combination therapy with cyclosporin A in the rat developing adjuvant arthritisInt J Tissue React21105111199910761540CohenAGoldmanJBromelain's therapy in rheumatoid arthritisPa Med J672730196414174138GroverAKSamsonSEBenefits of antioxidant supplements for knee osteoarthritis: rationale and realityNutr J151201610.1186/s12937-015-0115-z26728196